Patents by Inventor Sébastien COMBES

Sébastien COMBES has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS
    Publication number: 20240124938
    Abstract: The present invention relates to the field of oncology. laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking: to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 18, 2024
    Inventors: Christophe LACHAUD, Sébastien COMBES, Sébastien ABEL, Gilles AUDOLY, Sara BERRADA
  • Xanthine derivative inhibitors of BET proteins
    Patent number: 11225481
    Abstract: This invention relates to xanthine derivative compounds that are inhibitors of BET bromodomains proteins, the method of preparation thereof and applications thereof.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: January 18, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Xavier Morelli, Sébastien Combes, Jean-Claude Guillemot, Stéphanie Betzi, Yves Collette, Philippe Roche, Adrien Lugari, Sabine Milhas, Brigitt Raux, Iuliia Voitovich
  • Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins
    Patent number: 11180510
    Abstract: The present invention relates to a compound having the following formula (I): (I) wherein: —R is a (C1-C6)alkyl group; —R? is preferably H; —Ar is a (C5-C12)arylene radical; —X1 is —C(?O)—or —SO2—; and —R? is chosen from the group consisting of possibly substituted (C1-C6)alkyl, heteroaryl, (C5-C12)aryl, and (hetero)cycloalkyl groups, or a pharmaceutically acceptable salt and/or tautomeric form thereof, or its racemates, diastereomers or enantiomers.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: November 23, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Stéphane Betzi, Sébastien Combes, Yves Collette, Laurent Hoffer, Xavier Morelli, Brigit Raux, Philippe Roche, Iuliia Voitovich
  • XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS
    Publication number: 20200377522
    Abstract: The present invention relates to a compound having the following formula (I): (I) wherein: —R is a (C1-C6)alkyl group; —R? is preferably H; —Ar is a (C5-C12)arylene radical; —X1 is —C(?O)— or —SO2—; and —R? is chosen from the group consisting of possibly substituted (C1-C6)alkyl, heteroaryl, (C5-C12)aryl, and (hetero)cycloalkyl groups, or a pharmaceutically acceptable salt and/or tautomeric form thereof, or its racemates, diastereomers or enantiomers
    Type: Application
    Filed: November 6, 2018
    Publication date: December 3, 2020
    Inventors: Stéphane BETZI, Sébastien COMBES, Yves COLLETTE, Laurent HOFFER, Xavier MORELLI, Brigit RAUX, Philippe ROCHE, Iuliia VOITOVICH
  • XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS
    Publication number: 20190292186
    Abstract: This invention relates to xanthine derivative compounds that are inhibitors of BET bromodomains proteins, the method of preparation thereof and applications thereof.
    Type: Application
    Filed: December 27, 2016
    Publication date: September 26, 2019
    Inventors: Xavier MORELLI, Sébastien COMBES, Jean-Claude GUILLEMOT, Stéphanie BETZI, Yves COLLETTE, Philippe ROCHE, Adrein LUGARI, Sabine MILHAS, Brigit RAUX, luliia VOITOVICH
  • Apoptosis inducing compounds
    Patent number: 9193699
    Abstract: Provided are compounds of formula (I): wherein R1, R2, R3, R4 and R5 are independently selected from the group comprising, inter aliae, H, optionally substituted, branched or linear C1-C12 alkyl, halogen atom and C1-C12 haloalkyl, and wherein A represents a single bond or an optionally substituted C1-C6 alkylene radical, notably useful for the treatment of human cancers.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: November 24, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITÉ D'AIX-MARSEILLE, L'INSTITUT PAOLI-CALMETTES
    Inventors: Marc Lopez, Yves Collette, Lynda Mezil, Jean-Michel Brunel, Sebastien Combes
  • APOPTOSIS INDUCING COMPOUNDS
    Publication number: 20140296227
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4 and R5 are independently selected from the group comprising, inter aliae, H, optionally substituted, branched or linear C1-C12 alkyl, halogen atom and C1-C12 haloalkyl, and wherein A represents a single bond or an optionally substituted C1-C6 alkylene radical, notably useful for the treatment of human neoplasms.
    Type: Application
    Filed: October 4, 2012
    Publication date: October 2, 2014
    Inventors: Marc Lopez, Yves Collette, Lynda Mezil, Jean-Michel Brunel, Sebastien Combes